Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry

Rachel Kenney, Mengling Liu, Sachi Patil, Raed Alroughani, Radek Ampapa, Roberto Bergamaschi, Cavit Boz, Helmut Butzkueven, Jose Cabrera Gomez, Elisabetta Cartechini, Sara Eichau Madueño, Diana Ferraro, Francois Grand-Maison, Franco Granella, Dana Horakova, Guillermo Izquierdo Ayuso, Tomas Kalincik, Jana Lizrova Preiningerova, Alessandra Lugaresi, Marco OnofrjSerkan Ozakbas, Francesco Patti, Patrizia Sola, Aysun Soysal, Daniele Litterio A. Spitaleri, Murat Terzi, Recai Turkoglu, Vincent van Pesch, Shiv Saidha, Lorna E. Thorpe, Steven L. Galetta, Laura J. Balcer, Ilya Kister, Tim Spelman, the MSBase Study Group

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)


Background: Short-term outcomes of optic neuritis (ON) have been well characterized. Limited data exists on longer-term visual outcomes in patients who present with ON. The large MSBase registry allows for characterization of long-term visual outcomes after ON. Methods: Via the MSBase Registry, data on patients from 41 centers was collected during routine clinical and research visits. Physical and visual disability were measured using the expanded disability status scale (EDSS) and the visual function score (VFS). Inclusion criteria for this analysis included age ≥ 18 years, clinically isolated syndrome (CIS), ON-onset, baseline visit within 6 months of onset, and at least one follow-up visit. Survival analysis was used to evaluate the association of disease-modifying treatment with time to conversion to clinically definite MS or sustained EDSS/VFS progression. Results: Data from 60,933 patients were obtained from the MSBase registry in July 2019. Of these, 1317 patients met inclusion criteria; 935 were treated at some point in disease course, while 382 were never treated. At baseline, mean age was 32.3 ± 8.8 years, 74% were female, median EDSS was 2 (IQR 1–2), and median VFS was 1 (IQR 0–2). Median follow-up time was 5.2 years (IQR 2.4–9.3). Treatment was associated with reduced risk and delayed conversion to clinically definite MS (HR = 0.70, p < 0.001), sustained EDSS progression (HR = 0.46, p < 0.0001) and sustained VFS (HR = 0.41, p < 0.001) progression. Conclusions: In the MSBase cohort, treatment after ON was associated with better visual and neurological outcomes compared to no treatment. These results support early treatment for patients presenting with ON as the first manifestation of MS.

Original languageEnglish
Article number118067
Number of pages10
JournalJournal of the Neurological Sciences
Publication statusPublished - 15 Nov 2021


  • Clinically isolated syndrome
  • Expanded disability status scale (EDSS)
  • MSBase registry
  • Optic neuritis
  • Vision

Cite this